Biologics and Biosimilars Industry Research Report 2025

Summary

According to APO Research, The global Biologics and Biosimilars market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Biologics and Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Pfizer, AbbVie, United Laboratory and Tonghua Dongbao, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.

The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Biologics and Biosimilars Segment by Company

Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Pfizer
AbbVie
United Laboratory
Tonghua Dongbao
Sobi
Novo Nordisk
Kanghong Pharma
Innovent Biologics
Gan&Lee
Eli Lilly
Changchun High Tech
Celltrion
Biogen
Amgen
3SBIO
Biologics and Biosimilars Segment by Type

Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Biologics and Biosimilars Segment by Application

Hospital
Retail Pharmacy
Other
Biologics and Biosimilars Segment by Application

Hospital
Retail Pharmacy
Other
Biologics and Biosimilars Segment by Region


North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Colombia
Middle East & Africa

Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biologics and Biosimilars companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Biologics and Biosimilars by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Monoclonal Antibodies
2.2.3 Interferon
2.2.4 Insulin
2.2.5 Vaccines
2.2.6 Others
2.3 Biologics and Biosimilars by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospital
2.3.3 Retail Pharmacy
2.3.4 Other
2.4 Assumptions and Limitations
3 Biologics and Biosimilars Breakdown Data by Type
3.1 Global Biologics and Biosimilars Historic Market Size by Type (2020-2025)
3.2 Global Biologics and Biosimilars Forecasted Market Size by Type (2026-2031)
4 Biologics and Biosimilars Breakdown Data by Application
4.1 Global Biologics and Biosimilars Historic Market Size by Application (2020-2025)
4.2 Global Biologics and Biosimilars Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Biologics and Biosimilars Market Perspective (2020-2031)
5.2 Global Biologics and Biosimilars Growth Trends by Region
5.2.1 Global Biologics and Biosimilars Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Biologics and Biosimilars Historic Market Size by Region (2020-2025)
5.2.3 Biologics and Biosimilars Forecasted Market Size by Region (2026-2031)
5.3 Biologics and Biosimilars Market Dynamics
5.3.1 Biologics and Biosimilars Industry Trends
5.3.2 Biologics and Biosimilars Market Drivers
5.3.3 Biologics and Biosimilars Market Challenges
5.3.4 Biologics and Biosimilars Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Biologics and Biosimilars Players by Revenue
6.1.1 Global Top Biologics and Biosimilars Players by Revenue (2020-2025)
6.1.2 Global Biologics and Biosimilars Revenue Market Share by Players (2020-2025)
6.2 Global Biologics and Biosimilars Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Biologics and Biosimilars Head Office and Area Served
6.4 Global Biologics and Biosimilars Players, Product Type & Application
6.5 Global Biologics and Biosimilars Manufacturers Established Date
6.6 Global Biologics and Biosimilars Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Biologics and Biosimilars Market Size (2020-2031)
7.2 North America Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Biologics and Biosimilars Market Size by Country (2020-2025)
7.4 North America Biologics and Biosimilars Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Biologics and Biosimilars Market Size (2020-2031)
8.2 Europe Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Biologics and Biosimilars Market Size by Country (2020-2025)
8.4 Europe Biologics and Biosimilars Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Biologics and Biosimilars Market Size (2020-2031)
9.2 Asia-Pacific Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Biologics and Biosimilars Market Size by Country (2020-2025)
9.4 Asia-Pacific Biologics and Biosimilars Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Biologics and Biosimilars Market Size (2020-2031)
10.2 South America Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Biologics and Biosimilars Market Size by Country (2020-2025)
10.4 South America Biologics and Biosimilars Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Biologics and Biosimilars Market Size (2020-2031)
11.2 Middle East & Africa Biologics and Biosimilars Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Biologics and Biosimilars Market Size by Country (2020-2025)
11.4 Middle East & Africa Biologics and Biosimilars Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Sanofi
12.1.1 Sanofi Company Information
12.1.2 Sanofi Business Overview
12.1.3 Sanofi Revenue in Biologics and Biosimilars Business (2020-2025)
12.1.4 Sanofi Biologics and Biosimilars Product Portfolio
12.1.5 Sanofi Recent Developments
12.2 Johnson & Johnson
12.2.1 Johnson & Johnson Company Information
12.2.2 Johnson & Johnson Business Overview
12.2.3 Johnson & Johnson Revenue in Biologics and Biosimilars Business (2020-2025)
12.2.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
12.2.5 Johnson & Johnson Recent Developments
12.3 Novartis
12.3.1 Novartis Company Information
12.3.2 Novartis Business Overview
12.3.3 Novartis Revenue in Biologics and Biosimilars Business (2020-2025)
12.3.4 Novartis Biologics and Biosimilars Product Portfolio
12.3.5 Novartis Recent Developments
12.4 Merck
12.4.1 Merck Company Information
12.4.2 Merck Business Overview
12.4.3 Merck Revenue in Biologics and Biosimilars Business (2020-2025)
12.4.4 Merck Biologics and Biosimilars Product Portfolio
12.4.5 Merck Recent Developments
12.5 Roche
12.5.1 Roche Company Information
12.5.2 Roche Business Overview
12.5.3 Roche Revenue in Biologics and Biosimilars Business (2020-2025)
12.5.4 Roche Biologics and Biosimilars Product Portfolio
12.5.5 Roche Recent Developments
12.6 Pfizer
12.6.1 Pfizer Company Information
12.6.2 Pfizer Business Overview
12.6.3 Pfizer Revenue in Biologics and Biosimilars Business (2020-2025)
12.6.4 Pfizer Biologics and Biosimilars Product Portfolio
12.6.5 Pfizer Recent Developments
12.7 AbbVie
12.7.1 AbbVie Company Information
12.7.2 AbbVie Business Overview
12.7.3 AbbVie Revenue in Biologics and Biosimilars Business (2020-2025)
12.7.4 AbbVie Biologics and Biosimilars Product Portfolio
12.7.5 AbbVie Recent Developments
12.8 United Laboratory
12.8.1 United Laboratory Company Information
12.8.2 United Laboratory Business Overview
12.8.3 United Laboratory Revenue in Biologics and Biosimilars Business (2020-2025)
12.8.4 United Laboratory Biologics and Biosimilars Product Portfolio
12.8.5 United Laboratory Recent Developments
12.9 Tonghua Dongbao
12.9.1 Tonghua Dongbao Company Information
12.9.2 Tonghua Dongbao Business Overview
12.9.3 Tonghua Dongbao Revenue in Biologics and Biosimilars Business (2020-2025)
12.9.4 Tonghua Dongbao Biologics and Biosimilars Product Portfolio
12.9.5 Tonghua Dongbao Recent Developments
12.10 Sobi
12.10.1 Sobi Company Information
12.10.2 Sobi Business Overview
12.10.3 Sobi Revenue in Biologics and Biosimilars Business (2020-2025)
12.10.4 Sobi Biologics and Biosimilars Product Portfolio
12.10.5 Sobi Recent Developments
12.11 Novo Nordisk
12.11.1 Novo Nordisk Company Information
12.11.2 Novo Nordisk Business Overview
12.11.3 Novo Nordisk Revenue in Biologics and Biosimilars Business (2020-2025)
12.11.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
12.11.5 Novo Nordisk Recent Developments
12.12 Kanghong Pharma
12.12.1 Kanghong Pharma Company Information
12.12.2 Kanghong Pharma Business Overview
12.12.3 Kanghong Pharma Revenue in Biologics and Biosimilars Business (2020-2025)
12.12.4 Kanghong Pharma Biologics and Biosimilars Product Portfolio
12.12.5 Kanghong Pharma Recent Developments
12.13 Innovent Biologics
12.13.1 Innovent Biologics Company Information
12.13.2 Innovent Biologics Business Overview
12.13.3 Innovent Biologics Revenue in Biologics and Biosimilars Business (2020-2025)
12.13.4 Innovent Biologics Biologics and Biosimilars Product Portfolio
12.13.5 Innovent Biologics Recent Developments
12.14 Gan&Lee
12.14.1 Gan&Lee Company Information
12.14.2 Gan&Lee Business Overview
12.14.3 Gan&Lee Revenue in Biologics and Biosimilars Business (2020-2025)
12.14.4 Gan&Lee Biologics and Biosimilars Product Portfolio
12.14.5 Gan&Lee Recent Developments
12.15 Eli Lilly
12.15.1 Eli Lilly Company Information
12.15.2 Eli Lilly Business Overview
12.15.3 Eli Lilly Revenue in Biologics and Biosimilars Business (2020-2025)
12.15.4 Eli Lilly Biologics and Biosimilars Product Portfolio
12.15.5 Eli Lilly Recent Developments
12.16 Changchun High Tech
12.16.1 Changchun High Tech Company Information
12.16.2 Changchun High Tech Business Overview
12.16.3 Changchun High Tech Revenue in Biologics and Biosimilars Business (2020-2025)
12.16.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
12.16.5 Changchun High Tech Recent Developments
12.17 Celltrion
12.17.1 Celltrion Company Information
12.17.2 Celltrion Business Overview
12.17.3 Celltrion Revenue in Biologics and Biosimilars Business (2020-2025)
12.17.4 Celltrion Biologics and Biosimilars Product Portfolio
12.17.5 Celltrion Recent Developments
12.18 Biogen
12.18.1 Biogen Company Information
12.18.2 Biogen Business Overview
12.18.3 Biogen Revenue in Biologics and Biosimilars Business (2020-2025)
12.18.4 Biogen Biologics and Biosimilars Product Portfolio
12.18.5 Biogen Recent Developments
12.19 Amgen
12.19.1 Amgen Company Information
12.19.2 Amgen Business Overview
12.19.3 Amgen Revenue in Biologics and Biosimilars Business (2020-2025)
12.19.4 Amgen Biologics and Biosimilars Product Portfolio
12.19.5 Amgen Recent Developments
12.20 3SBIO
12.20.1 3SBIO Company Information
12.20.2 3SBIO Business Overview
12.20.3 3SBIO Revenue in Biologics and Biosimilars Business (2020-2025)
12.20.4 3SBIO Biologics and Biosimilars Product Portfolio
12.20.5 3SBIO Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings